Open Orphan PLC #ORPH – NEJM Opinion Piece July 22, 2021 – Posted in: Open Orphan (ORPH)

The New England Journal of Medicine (NEJM) publishes editorial relating to Human Challenge Programme Open Orphan (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that an editorial opinion piece regarding the UK Government’s Human Challenge Programme has been published in the latest edition of the New England Journal of Medicine (NEJM). The piece, titled ‘Establishing the Model during an Evolving Pandemic’, explores the extensive…

OPEN ORPHAN #ORPH – Result of AGM July 21, 2021 – Posted in: Blog, Open Orphan (ORPH)

21 July, 2021 Open Orphan plc (“Open Orphan”, the “Company”) Result of Annual General Meeting Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that at the Annual General Meeting held at 12 noon today, all resolutions were duly passed. For further information please contact: Open Orphan plc +353 (0) 1 644 0007 Cathal…

Open Orphan (ORPH) Demerger Update June 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Demerger Update Further to Open Orphan’s announcement on 14 June 2021 in relation to the distribution in specie, the boards of Open Orphan and Poolbeg Pharma are pleased to announce Poolbeg’s intention to seek admission of its shares to trading on AIM, a market of the London Stock Exchange (“Admission”). Funds raised as part of Admission will be used primarily to fund the clinical trial costs associated with the development of the Company’s POLB 001 asset as a treatment for severe influenza and to acquire and…

Open Orphan (ORPH) Final Results to 31 December 2020 – Posted in: Blog, Open Orphan (ORPH)

Final Results to 31 December 2020 Important year of transition following the various merger and acquisition activities in 2019 and January 2020 Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its audited results for the 12 months to 31 December 2020. Following the acquisition of hVIVO in January of last year, 2020 was a…

Open Orphan – Upcoming Investor Events July 8, 2020 – Posted in: Open Orphan (ORPH)

8th July, 2020 Open Orphan Plc (“Open Orphan” or the “Company”) Upcoming Investor Events Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is delighted to be attending and presenting at a series of investor events from the 9th to 11th July 2020. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance for all of…

Open Orphan presenting at Hardman & Co virtual Investor Forum on 9th July, 2020 June 17, 2020 – Posted in: Open Orphan (ORPH)

Hardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020 We are delighted to announce that Open Orphan will be presenting at our next Investor Forum on Thursday 9th July. The Investor Forum connects investors with companies looking for capital. Each company will present for 10-15 minutes, followed by an opportunity for Q&A. Open Orphan (ORPH) is a publicly traded company on the London AIM and Euronext Growth stock exchanges.…

Open Orphan PLC (ORPH) Signs Preferred Partner Agreement November 11, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform company, is pleased to announce the signing of a preferred partner agreement between Open Orphan and Ipsen Group (“Ipsen”). The agreement selects Venn Life Sciences (“Venn”), which is part of the Open Orphan group, as the preferred partner for Ipsen’s Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. This partnership has already delivered substantial revenues for the Open Orphan group…

Open Orphan PLC #ORPH – NEJM Opinion Piece July 22, 2021 – Posted in: Open Orphan (ORPH)

OPEN ORPHAN #ORPH – Result of AGM July 21, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (ORPH) Demerger Update June 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (ORPH) Final Results to 31 December 2020 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan – Upcoming Investor Events July 8, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan presenting at Hardman & Co virtual Investor Forum on 9th July, 2020 June 17, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan PLC (ORPH) Signs Preferred Partner Agreement November 11, 2019 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL